middle.news
How Is ResMed Driving 11% Revenue Growth Amid Patent Challenges?
8:28am on Monday 2nd of February, 2026 AEDT
•
Healthcare
Read Story
How Is ResMed Driving 11% Revenue Growth Amid Patent Challenges?
8:28am on Monday 2nd of February, 2026 AEDT
Key Points
11% revenue growth driven by increased device and mask sales
Gross margin improved to 61.8% due to manufacturing efficiencies
Restructuring expenses recorded for workforce planning
Strong liquidity with $1.4 billion cash and $1.5 billion credit facility available
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RESMED (ASX:RMD)
OPEN ARTICLE